Stallion India Fluorochemicals Posts 31.8% Revenue Rise in Q2 FY27 Amid Launch of Specialty Gases Unit
H1 FY27 revenue climbs 22.1% to ₹26,404.90 lakh, with Khalapur Helium facility now operational supplying semiconductor and healthcare sectors
Stallion India Fluorochemicals Limited announced a 31.8% year-on-year revenue increase to ₹13,937.33 lakh in Q2 FY27 and sustained double-digit growth in H1 FY27 revenue. The company also commenced operations at its Khalapur high-purity helium facility, targeting semiconductor and healthcare markets.
Stallion India Fluorochemicals Limited
General / Other
Stallion India Fluorochemicals Limited reported a 31.8% year-on-year increase in total revenue to ₹13,937.33 lakh for the quarter ending September 30, 2026, with half-year revenue up 22.1% to ₹26,404.90 lakh. The company also announced the operational commencement of its Khalapur high-purity helium gas facility targeting specialty gas markets such as semiconductors and healthcare.
The quarter saw operating profit after tax (PAT), excluding non-cash employee stock option expenses, increase by 4.78% year-on-year to ₹1,196.21 lakh in Q2 FY27 and by 40.2% to ₹3,052.78 lakh for H1 FY27.
The Khalapur Helium Facility is fully operational, supplying high-purity gases used in semiconductor manufacturing, MRI healthcare, aerospace, and defense industries, with sourcing partnerships established with SOC Dubai and Qatar.
The company clarified that the reported non-cash ESOP charge of ₹950.92 lakh under Ind AS 102 has no impact on cash flow and is an accounting provision only, explaining adjusted earnings present the true operating profitability.
Looking ahead, Stallion India Fluorochemicals is progressing projects to expand capacity and backward integration including scaling specialty gases at Khalapur, expanding the Mambattu facility, and advancing next-generation refrigerant molecule R-32 projects.
With over 30 years in the refrigerants and industrial gases markets and five strategic plants across India, the company continues to diversify into high-value specialty segments.
Highlights
- Q2 FY27 revenue grew 31.8% year-on-year to ₹13,937.33 lakh
- H1 FY27 revenue reached ₹26,404.90 lakh, up 22.1%
- Operating PAT for H1 FY27 increased by 40.2% to ₹3,052.78 lakh, before ESOP provisions
- Khalapur high-purity helium gas facility commenced operations, targeting semiconductor and healthcare sectors
- Non-cash ESOP charge of ₹950.92 lakh recognized with no impact on cash flow
- Strategic expansion projects include Mambattu facility growth and R-32 backward integration
Key Data Snapshot
What happened
- Stallion India Fluorochemicals posted 31.8% year-on-year revenue growth in Q2 FY27 to ₹13,937.33 lakh and 22.1% growth in H1 FY27 revenue to ₹26,404.90 lakh.
- Operating profit after tax before ESOP provisions rose 4.78% in Q2 FY27 and 40.2% in H1 FY27.
- The company started operations at its Khalapur Helium Facility supplying high-purity specialty gases for semiconductor, MRI healthcare, aerospace, and defense industries.
- The Khalapur facility is supported by sourcing partnerships with SOC Dubai and Qatar.
Key details
- Non-cash employee stock option compensation amounting to ₹950.92 lakh was recognized in H1 FY27 under Ind AS 102, which is a book entry with no cash outflow.
- Adjusted operating profitability metrics exclude this ESOP charge for clarity on core earnings.
- The company aims to expand capacity through the Mambattu plant and backward integrate next-generation refrigerant R-32.
- Stallion India Fluorochemicals has over 30 years of experience with five manufacturing plants located in Khalapur, Ghiloth, Manesar, and Panvel.
Strategic context
- The high-purity specialty gases segment like helium targets high-tech industries including semiconductors, healthcare MRI, aerospace, and defense.
- This diversification aligns with the company’s roadmap involving portfolio depth and regional manufacturing reach expansion.
- Partnerships with global suppliers support stable supply chains for specialty gases.
Highlights
- Q2 FY27 revenue grew 31.8% year-on-year to ₹13,937.33 lakh
- H1 FY27 revenue reached ₹26,404.90 lakh, up 22.1%
- Operating PAT for H1 FY27 increased by 40.2% to ₹3,052.78 lakh, before ESOP provisions
- Khalapur high-purity helium gas facility commenced operations, targeting semiconductor and healthcare sectors
- Non-cash ESOP charge of ₹950.92 lakh recognized with no impact on cash flow
- Strategic expansion projects include Mambattu facility growth and R-32 backward integration
Disclosures
- Ind AS 102 Employee Benefits – Share-based Payment
Source Information
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
State Bank of India Engages with Global Institutional Investors in Singapore Hosted by Bank of America
State Bank of India conducted a meeting with major global institutional investors in Singapore on 17th November 2026, hosted by Bank of America, where only publicly available information was discussed.
Read Full StoryIndia Glycols Posts Rs. 358.18 Crore Revenue and Rs. 39.34 Crore EBITDA in Q2 FY27 Post-Demerger
India Glycols Limited announced its standalone unaudited financial results for the quarter ended September 30, 2026, reporting revenue of Rs. 358.18 crore and EBITDA of Rs. 39.34 crore after demerging its Spirits & Biofuel and Biopharma undertakings into separately listed entities.
Read Full StoryArtemis Medicare Services Limited Opens Special Window for Transfer and Dematerialisation of Physical Securities
Artemis Medicare Services Limited has announced the opening of a Special Window for the transfer and dematerialisation of physical securities through a public notice published on November 17, 2026. This facility allows shareholders to convert their physical share certificates to electronic format within the specified period.
Read Full Story